Reports & Testimonies
Recommendations Database
GAO’s recommendations database contains report recommendations that still need to be addressed. GAO’s priority recommendations are those that we believe warrant priority attention. We sent letters to the heads of key departments and agencies, urging them to continue focusing on these issues. Below you can search only priority recommendations, or search all recommendations.
Our recommendations help congressional and agency leaders prepare for appropriations and oversight activities, as well as help improve government operations. Moreover, when implemented, some of our priority recommendations can save large amounts of money, help Congress make decisions on major issues, and substantially improve or transform major government programs or agencies, among other benefits.
As of October 25, 2020, there are 4812 open recommendations, of which 473 are priority recommendations. Recommendations remain open until they are designated as Closed-implemented or Closed-not implemented.
Browse or Search Open Recommendations
Have a Question about a Recommendation?
- For questions about a specific recommendation, contact the person or office listed with the recommendation.
- For general information about recommendations, contact GAO's Audit Policy and Quality Assurance office at (202) 512-6100 or apqa@gao.gov.
Results:
Federal Agency: "Executive Office of the President: Office of National Drug Control Policy"
GAO-20-59, Feb 27, 2020
Phone: (202) 512-9342
Agency: Executive Office of the President: Office of National Drug Control Policy
Status: Open
Comments: The Office of the National Drug Control Policy did not state whether or not it concurred with this recommendation. As of June 2020, we had not received information pertaining to planned actions for this recommendation. Once the office states that it has taken action, we plan to verify whether implementation has occurred.
Agency: Executive Office of the President: Office of National Drug Control Policy
Status: Open
Comments: The Office of the National Drug Control Policy did not state whether or not it concurred with this recommendation. As of June 2020, we had not received information pertaining to planned actions for this recommendation. Once the office states that it has taken action, we plan to verify whether implementation has occurred.
Agency: Executive Office of the President: Office of National Drug Control Policy
Status: Open
Comments: The Office of the National Drug Control Policy did not state whether or not it concurred with this recommendation. As of June 2020, we had not received information pertaining to planned actions for this recommendation. Once the office states that it has taken action, we plan to verify whether implementation has occurred.
GAO-20-124, Dec 18, 2019
Phone: (202) 512-8777
Agency: Executive Office of the President: Office of National Drug Control Policy
Status: Open
Comments: When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.
Agency: Executive Office of the President: Office of National Drug Control Policy
Status: Open
Comments: When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.
Agency: Executive Office of the President: Office of National Drug Control Policy
Status: Open
Comments: When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.
Agency: Executive Office of the President: Office of National Drug Control Policy
Status: Open
Comments: When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.
GAO-18-205, Mar 29, 2018
Phone: (202) 512-8777
Agency: Executive Office of the President: Office of National Drug Control Policy
Status: Open
Comments: In the 60-day letter, dated June 28, 2018, ONDCP officials noted a number of federal initiatives underway to evaluate the timeliness, accuracy, and accessibility of overdose data. For example, ONDCP discussed its participation in a new Interagency Working Group led by the National Security Council to consider the implementation of overdose tracking and analytic capability, such as the expansion of ODMAP, as well as evaluating the appropriate federal role to engage in this initiative. In March 2019, ONDCP reported that it had suspended its ODMAP working group in the summer of 2018, after determining that this effort would be more effective for the Department of Justice's Bureau of Justice Assistance (BJA) and the Centers for Disease Control and Prevention (CDC) to work together through the Comprehensive Opioid Abuse Program Initiative. Nevertheless, as of April 2019, ONDCP officials reported that they continue to provide grant funding and training and technical assistance towards the expansion and use of ODMAP by state and local jurisdictions. Further, ONDCP reported supporting other federal data initiatives, such as providing funding to develop software for the CDC's National Center for Health Statistics Mortality Data that could better read narrative fields in death certificates to improve the timeliness and accuracy of the data. While ONDCP's efforts are directed towards supporting and improving existing data sources, the recommendation asks ONDCP to lead a review which it has not done. Further, ONDCP's initiatives to date have not addressed issues raised in our report related to balancing law enforcement's access to restricted health data while protecting patient privacy. We will continue to monitor ONDCP's efforts towards implementing this recommendation.
Agency: Executive Office of the President: Office of National Drug Control Policy
Status: Open
Comments: In the 60-day letter, dated June 28, 2018, ONDCP officials stated that they had engaged with leaders from HIDTA participating in the Heroin Response Strategy to develop performance measures. According to ONDCP, as of early May 2018, eleven performance measures had been established--nine mandatory measures and two optional measures--and four of these measures constitute outcome-oriented measures. The June letter also noted that the HIDTA Performance Management Process database was being updated to reflect the new measures and ONDCP expected the system to be fully operational by the end of September 2018. In March 2019, ONDCP reported that, throughout the summer of 2018, it had revisited the performance measures it had developed and settled on ten revised performance measures (eight mandatory measures and two optional measures) for the newly branded Opioid Response Strategy (formerly known as the Heroin Response Strategy). According to ONDCP, these measures were implemented in HIDTA's Performance Management Process as of February 1, 2019. We will continue to coordinate with ONDCP to obtain documentation of these new measures. Once we obtain them, we will review and work toward closing the recommendation, as appropriate.